This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and
pharmacodynamics (PD) of TD-1473 in subjects with moderately-to-severely active UC over 28
days. This exploratory study will also serve as a signal seeking endeavor to demonstrate
biologic effect associated with TD-1473 through biomarker analysis and clinical, endoscopic,
and histologic assessments.
Phase:
Phase 1
Details
Lead Sponsor:
Theravance Biopharma Theravance Biopharma R & D, Inc.